Chronic myeloproliferative disease
ICD-10 D47.1 is a billable code used to indicate a diagnosis of chronic myeloproliferative disease.
Chronic myeloproliferative disease (CMPD) encompasses a group of hematological disorders characterized by the overproduction of blood cells due to clonal proliferation of hematopoietic stem cells. This condition is classified under neoplasms of uncertain behavior, indicating that while it involves abnormal cell growth, it does not fit neatly into benign or malignant categories. CMPD can lead to various complications, including splenomegaly, thrombosis, and transformation into acute myeloid leukemia (AML) or myelodysplastic syndromes. Patients may present with symptoms such as fatigue, night sweats, and unexplained weight loss. Diagnosis typically involves blood tests showing elevated cell counts, bone marrow biopsy, and genetic testing for mutations such as JAK2 V617F. Surveillance is crucial as the disease can progress, necessitating regular monitoring of blood counts and clinical symptoms to manage potential complications effectively.
Detailed patient history, laboratory results, and treatment plans must be documented.
Diagnosis and management of CMPD, monitoring for progression, and treatment of complications.
Ensure accurate documentation of blood counts and any genetic testing results.
Comprehensive treatment plans, including chemotherapy or targeted therapy regimens.
Management of patients with CMPD who may progress to acute leukemia.
Document any transformation of the disease and the rationale for treatment changes.
Used to monitor blood cell counts in patients with CMPD.
Document the reason for the CBC and any abnormal findings.
Hematologists should ensure that all relevant lab results are included in the patient's record.
Chronic myeloproliferative disease refers to a group of disorders characterized by the overproduction of blood cells due to clonal proliferation of hematopoietic stem cells. It includes conditions like polycythemia vera and essential thrombocythemia.
